caa a22 4500 469121734 CHVBK 20180323133141.0 cr unu---uuuuu 170328e19920201xx s 000 0 eng 10.1007/BF02246254 doi (NATIONALLICENCE)springer-10.1007/BF02246254 Long-term treatment with moclobemide. An open-label, non-comparative, multiple-distributed study in patients with a major depressive episode as defined by DSM-III [Elektronische Daten] [E. Moll, M. Stabl, R. Wegscheider, R. Amrein] Evaluation of 247 patients receiving long-term moclobemide treatment showed that it was effective as an antidepressant, as measured both by decrease in HAMD mean total score and the doctor's evaluation of therapeutic effect. In patients who had been treated for 6 months or less, results were less favourable (ratings of ‘very good' or ‘good' in 31.5%, compared with 81.3% in patients treated for more than 6 months). This was due to a higher number of drop-outs, as a result of insufficient efficacy in the first 6 months. In those patients who responded favourably, 9.2% relapsed within 6 months of commencing treatment; of the remaining responders, 16% relapsed during months 7-12. In terms of the doctor's evaluation of side-effects, tolerability was ‘very good' or ‘good' in 88.2%. Springer-Verlag, 1992 Moclobemide nationallicence Major depression nationallicence Long-term treatment nationallicence Moll E. Clinical Research Department (PRCT-P), F. Hoffmann-La Roche Ltd, CH-4002, Basel, Switzerland aut Stabl M. Clinical Research Department (PRCT-P), F. Hoffmann-La Roche Ltd, CH-4002, Basel, Switzerland aut Wegscheider R. Clinical Research Department (PRCT-P), F. Hoffmann-La Roche Ltd, CH-4002, Basel, Switzerland aut Amrein R. Clinical Research Department (PRCT-P), F. Hoffmann-La Roche Ltd, CH-4002, Basel, Switzerland aut Psychopharmacology Springer-Verlag 106(1992-02-01), S120-S122 0033-3158 106<S120 1992 106 213 https://doi.org/10.1007/BF02246254 text/html Onlinezugriff via DOI 1 research-article jats NATIONALLICENCE 856 40 https://doi.org/10.1007/BF02246254 text/html Onlinezugriff via DOI NATIONALLICENCE 700 1- Moll E. Clinical Research Department (PRCT-P), F. Hoffmann-La Roche Ltd, CH-4002, Basel, Switzerland aut NATIONALLICENCE 700 1- Stabl M. Clinical Research Department (PRCT-P), F. Hoffmann-La Roche Ltd, CH-4002, Basel, Switzerland aut NATIONALLICENCE 700 1- Wegscheider R. Clinical Research Department (PRCT-P), F. Hoffmann-La Roche Ltd, CH-4002, Basel, Switzerland aut NATIONALLICENCE 700 1- Amrein R. Clinical Research Department (PRCT-P), F. Hoffmann-La Roche Ltd, CH-4002, Basel, Switzerland aut NATIONALLICENCE 773 0- Psychopharmacology Springer-Verlag 106(1992-02-01), S120-S122 0033-3158 106<S120 1992 106 213 Metadata rights reserved Springer special CC-BY-NC licence nationallicence BK010053 XK010053 XK010000 NATIONALLICENCE NATIONALLICENCE NL-springer